A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
Latest Information Update: 05 Nov 2025
At a glance
- Drugs Baricitinib (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BARICADE-DELAY
- Sponsors Eli Lilly and Company
Most Recent Events
- 05 Nov 2025 New trial record